RNA-based immunotherapeutics for the treatment of cancer and viral diseases
Rigontec has raised €28M across 3 funding rounds from 8 investors, most recently a Series A round in Sep 2016. Based in Bonn, Germany; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
